WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. INVEGA® SUSTENNA® (paliperidone palmitate) is not approved for the treatment of patients with dementia-related psychosis. [See Warnings and Precautions]
Media Articles Related to Invega Sustenna (Paliperidone)
Schizophrenia: Impaired activity of the selective dopamine neurons
Source: Schizophrenia News From Medical News Today [2015.02.19]
German-American team of researchers finds neurophysiological correlates for cognitive and emotional symptoms in a Schizophrenia mouse model.
Schizophrenia and weight gain: A new explanation?
Source: Schizophrenia News From Medical News Today [2015.02.06]
Cannabinoids may be involved in the weight gain that occurs in people with schizophrenia who are treated with the antipsychotic olanzapine, according to a pilot study published in the Journal of...
There is not a single type of schizophrenia, as thought, but 8 different genetic diseases
Source: Schizophrenia News From Medical News Today [2015.02.05]
Researchers from the universities of Granada and Washington in St Louis break new ground in what could be an important first step towards better diagnosis and treatment of this diseaseScientists...
"Spark", a new public-private project created to develop a drug to fight the cognitive impairment associated with schizophrenia
Source: Schizophrenia News From Medical News Today [2015.01.28]
A public-private consortium led by the biotech Iproteos - based at Parc CientÃfic de Barcelona (PCB), and comprised by the biopharmaceutical company Ascil-Biopharma, the Institute for Biomedical...
Newron announces results of Phase I study of NW-3509, Phase II study in schizophrenia patients planned for Q2 2015
Source: Schizophrenia News From Medical News Today [2015.01.16]
Newron Pharmaceuticals S.p.A., a research and development company focused on novel CNS and pain therapies, has announced the completion of the first in man US Phase I study of its novel sodium...
Published Studies Related to Invega Sustenna (Paliperidone)
Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in
serotonin reuptake inhibitor-resistant obsessive-compulsive disorder. 
CONCLUSIONS: These results suggest that paliperidone augmentation is well
An integrated approach for establishing dosing recommendations: paliperidone for
the treatment of adolescent schizophrenia. 
The Food and Drug Administration recently approved Invega for the treatment of
schizophrenia in adolescents 12 to 17 years. If dosing recommendations for this
population would have been based only on the results of the single efficacy trial
included in this program, paliperidone dosing in adolescents might have been
limited to 3 mg/d in adolescents less than 51 kg and to 6 mg/d in adolescents
greater than or equal to 51 kg...
Bilastine: in allergic rhinitis and urticaria. 
Bilastine is an orally administered, second-generation antihistamine used in the
symptomatic treatment of seasonal or perennial allergic rhinoconjunctivitis and
urticaria. In two well designed phase III trials, 14 days' treatment with
bilastine was associated with a significantly lower area under the effect curve
(AUEC) for the reflective total symptom score (TSS) than placebo in patients with
symptomatic seasonal allergic rhinitis...
A randomized, placebo- and active-controlled study of paliperidone
extended-release as maintenance treatment in patients with bipolar I disorder
after an acute manic or mixed episode. 
patients with this disorder... CONCLUSIONS: Paliperidone ER significantly delayed the time to recurrence of any
Oral paliperidone: a review of its use in the management of schizoaffective disorder. [2011.06.01]
Oral paliperidone extended or prolonged release (Invega(R)) is an atypical antipsychotic, and is the first agent approved for the treatment of schizoaffective disorder. Paliperidone (or 9-hydroxyrisperidone) is the major active metabolite of the well known atypical antipsychotic risperidone, and its mechanism of action is thought to be the antagonism of dopamine D(2) and serotonin 5-HT(2A) receptors...
Clinical Trials Related to Invega Sustenna (Paliperidone)
Paliperidone Palmitate Efficacy and Safety in Bipolar Disorder Complicated by Alcoholism [Not yet recruiting]
Our primary specific aim is to examine the efficacy of Paliperidone extended release
Paliperidone Palmitate Injection (INVEGAÂ® SUSTENNAâ„¢) compared to placebo in decreasing manic
symptoms in patients with comorbid DSM-IV bipolar disorder and alcohol dependence. We
hypothesize that the Paliperidone Palmitate Injection (INVEGAÂ® SUSTENNAâ„¢) treated group will
have a statistically significant advantage on improvement in manic symptoms. They will also
have higher rate of treatment response and remission.
A Study to Evaluate the Response to Treatment and Safety of Flexible Dose Treatment With Extended-release Paliperidone in Patients With Schizophrenia [Recruiting]
This study will explore the efficacy and safety of flexibly dosed paliperidone ER in
subjects with schizophrenia.
At the end of 12 months, flexible dose paliperidone treatment is expected to improve
functionality and satisfaction of schizophrenia patients significantly as measured by PSP.
The expected increase in PSP score is approximately 10-20%
Invega for the Treatment of Mania in Children and Adolescents Ages 6-17 With Bipolar Disorder [Recruiting]
This will be an 8-week open-label trial, using daily doses of paliperidone (Invega) in the
treatment of children and adolescents who meet DSM-IV criteria of Bipolar I, Bipolar II, or
Bipolar Spectrum Disorder. Specific hypotheses are as follows:
Hypothesis 1: Bipolar Disorder symptomatology in children and adolescents with DSM-IV
Bipolar I, Bipolar II, or Bipolar Spectrum Disorder will be responsive to Invega treatment.
Hypothesis 2: Invega - associated improvement in bipolar disorder symptomatology in children
and adolescents will translate into improved functional capacities (neuropsychological,
social, and occupational), as well as an increased quality of life throughout treatment.
Hypothesis 2: Invega treatment will be safe and well tolerated as reflected by a low drop
out rate and absence of major side effects.
Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia [Recruiting]
Primary objective: To examine whether the switch to paliperidone ER from risperidone
improves cognitive function in stabilized patients with schizophrenia.
Secondary objectives: To compare the general clinical outcomes (efficacy and safety) after
switching to paliperidone ER from risperidone
A Study of Paliperidone Palmitate in Patients With Schizophrenia [Recruiting]
The primary objective of this study is to evaluate the efficacy of paliperidone palmitate as
compared with placebo in patients with schizophrenia. Secondary objectives of this study are
to evaluate the safety of paliperidone palmitate; to evaluate the improvement in global
symptoms as measured by the Clinical Global Impression - Severity (CGI-S) associated with
the use of paliperidone palmitate compared with placebo; and to explore the pharmacokinetics
of paliperidone palmitate through pharmacokinetic sampling.
Reports of Suspected Invega Sustenna (Paliperidone) Side Effects
Drug Dose Omission (179),
Device Leakage (78),
Drug Ineffective (77),
Weight Increased (72),
Product Quality Issue (61),
Condition Aggravated (53),
Psychotic Disorder (48),
Inappropriate Schedule of Drug Administration (47),
Injection Site Pain (47),
Hospitalisation (44), more >>